At a glance
ClinicalIndex Comparison RecordPhase 2Completed
Drug / intervention
Peginterferon alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Multicenter, Phase II, Open Label, Controlled Trial Evaluating the Response of Hepatitis C Virus (HCV) to Pegylated Interferon Alpha-2A and Ribavirin in Hemophilic Patients With and Without Coinfection With the Human Immunodeficiency Virus (HIV)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Feb 27, 2003·Updated Jul 30, 2008
In Brief
A Phase 2 clinical trial evaluating Peginterferon alfa-2a and Ribavirin for HIV Infections and 2 related conditions. Completed, across 1 site.
Detailed Summary
Pegylated interferon (PEG-interferon) and ribavirin are accepted treatments for hepatitis C virus (HCV) infection. However, HCV infection progresses differently in patients who are coinfected with HIV and in hemophiliacs. This study will evaluate the effectiveness of PEG-interferon and ribavirin for treating HCV in HIV infected hemophiliacs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Hepatitis C, Hemophilia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2002
First PostedFeb 2003
Study CompletionJun 2005
TodayJul 2026
First PostedFeb 27, 2003
Enrollment StartMar 1, 2002
Study CompletionJun 1, 2005
TodayJul 2, 2026
Posted 23.3 years ago
Interventions
Peginterferon alfa-2adrug
Ribavirindrug